Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

ENVIROMED · Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact

HORIZONStatus: SIGNED1 June 202230 November 2025EU funding €7,518,062Call HORIZON-HLTH-2021-IND-07

Pharmaceuticals have undoubtably made our world a better place, ensuring longer and healthier lives. However, pharmaceuticals and their active metabolites are rapidly emerging environmental toxicants. It is thus critical that we fully understand, and mitigate where nec-essary, the environmental impact resulting from their production, use and disposal. In this direction, ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals, a) impact of the processes in manufacturing the compound, and b) impact of the compound itself, during its lifecycle. The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, in the environment as it enables the better understanding the environmental impact of such compounds, throughout their lifecycle. It aims to offer (via extensive monitoring campaigns & scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro & in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment. Brief ideas about toxicity endpoints, available ecotoxicity databases, and expert systems employed for rapid toxicity predictions of ecotoxicity of pharmaceuticals will also be taken into account, in order to have a comprehensive approach to pharmaceuticals' Lifecycle Assessment (LCA). Moreover, the project aims at developing a set of technologies that enable greener and overall, more efficient pharmaceuticals production, which include: a) Green-by-design in-silico drug development; b) Novel sensing to allow reduction of rinsing chemicals and cycles; c) a robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction, using data assimilation based on chemical sensing and energy disaggregation/monitoring. Training activities and a robust exploitation

Consortium · 19 organisations

coordinator

RISA SICHERHEITSANALYSEN GMBH

DE · €902,500

participant

MITERA IDIOTIKI GENIKI, MAIEYTIKI,GYNAIKOLOGIKI KAI PAIDIATRIKI KLINIKI ANONYMI ETAIREIA

EL · €408,125

participant

TECHNISCHE UNIVERSITAET WIEN

AT · €1,155,937

participant

UAB METIS BALTIC

LT · €288,125

participant

UNIVERSITAET ULM

DE · €675,000

participant

ETHNICON METSOVION POLYTECHNION

EL · €380,000

participant

PFIZER IRELAND PHARMACEUTICALS

IE · €15,000

participant

CLOUDPHARM PRIVATE COMPANY

EL · €533,375

participant

INNOVATION IN RESEARCH & ENGINEERING SOLUTIONS

BE · €378,750

associatedPartner

FRAUNHOFER UK RESEARCH LIMITED

UK

associatedPartner

AGILENT TECHNOLOGIES LDA UK LIMITED

UK

participant

CONSIGLIO NAZIONALE DELLE RICERCHE

IT · €552,625

participant

HORIBA EUROPE GMBH

DE · €367,500

participant

ETAIREIA YDREYSEOS KAI APOCHETEFSEOS PROTEYOYSIS ANONIMI ETAIREIA

EL · €312,375

associatedPartner

ALPES LASERS SA

CH

participant

RESEARCH CENTER FOR NON DESTRUCTIVE TESTING GMBH

AT · €488,250

participant

NOVO NORDISK A/S

DK · €424,250

participant

CY.R.I.C CYPRUS RESEARCH AND INNOVATION CENTER LTD

CY · €365,000

participant

PLEGMA LABS TECHNOLOGIKES LYSEIS ANONYMOS ETAIRIA

EL · €271,250

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.